HeraMED appoints leading clinician to advisory board

Latest News

Perth-based medical technology company, HeraMED (ASX:HMD), has announced that researcher and physician Dr Paul A. Friedman of Mayo Clinic will join its advisory board.

Dr Friedman is the chair of the Department of Cardiovascular Medicine at the Mayo Clinic in Rochester, Minnesota.

He is certified in cardiovascular medicine and cardiac electrophysiology by the American Board of Internal Medicine and previously served as director of the Cardiac Implantable Device Lab at Mayo Clinic.

According to HeraMED CEO and co-founder David Groberman, ‶We are excited to welcome Dr Friedman to our advisory board. His considerable experience and depth of knowledge of the innovative medicine space will be greatly beneficial to HeraMED as it progresses its next phase of growth.

“We look forward to commencing our work with Dr Friedman and leveraging his considerable experience and network to create value for obstetricians and pregnant women across the world.”

HeraMED said Dr Friedman holds more than 40 patents, has issued more than 250 scientific research publications and has authored more than 60 book chapters. Currently, he is leading a research team that specialises in medical applications of Artificial Intelligence (AI) and machine learning.

Dr Friedman will act as a co-investigator, contributing his expertise to HeraMED’s co-venture with the Mayo Clinic, ‘OrionAI’ working in cooperation with his colleague Dr Abimbola Famuyide MD, Chair of the Department of Obstetrics who is the primary investigator of the project.